dichlororibofuranosylbenzimidazole has been researched along with tacrolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chen, SR; Hu, YM; Pan, HL | 1 |
| Hedvat, J; Lange, NW; Sabatino, DC; Salerno, DM | 1 |
2 other study(ies) available for dichlororibofuranosylbenzimidazole and tacrolimus
| Article | Year |
|---|---|
Casein kinase II inhibition reverses pain hypersensitivity and potentiated spinal N-methyl-D-aspartate receptor activity caused by calcineurin inhibitor.
Topics: Animals; Calcineurin Inhibitors; Casein Kinase II; Dichlororibofuranosylbenzimidazole; Excitatory Postsynaptic Potentials; Hyperalgesia; Male; Miniature Postsynaptic Potentials; N-Methylaspartate; Physical Stimulation; Posterior Horn Cells; Rats, Sprague-Dawley; Spinal Cord; Tacrolimus; Touch; Triazoles | 2014 |
Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients.
Topics: Benzimidazoles; Dichlororibofuranosylbenzimidazole; Humans; Immunosuppressive Agents; Organ Transplantation; Ribonucleosides; Tacrolimus; Transplant Recipients | 2022 |